Literature DB >> 35919366

Zollinger Ellison Syndrome Refractory to Medical Therapy in the Setting of Multiple Endocrine Neoplasia Type I.

Brendan R Martino1, Pedro Manibusan2.   

Abstract

Multiple Endocrine Neoplasia 1 (MEN1) syndrome is a genetic condition arising from a mutation of the MEN1 gene resulting in neuroendocrine tumor formation. Patients with MEN1 are at a higher risk of developing Zollinger-Ellison syndrome (ZES) due to the growth of neuroendocrine tumors called gastrinomas that release gastrin leading to hypersecretion of acid in the stomach resulting in severe ulcerative disease of the upper GI tract. Our case is a 42-year-old female with newly diagnosed MEN1 syndrome, presenting with acute abdominal pain and dyspepsia refractory to medical management including proton pump inhibitors (PPI) and H2 antagonists. ZES was biochemically confirmed with a secretin stimulation test and dotatate positron emission tomography/computed tomography (PET/CT) revealed multiple areas of hyper-metabolic activity within the gastrinoma triangle. However, no discrete masses could be appreciated on endoscopic ultrasound (EUS) or CT imaging that could provide a target for surgical intervention. This case elucidates not only the difficulty of gastrinoma localization in medically refractory ZES but also reinforces the need to screen patients with MEN1 presenting with acute abdominal pain and dyspepsia for ZES.
Copyright © 2022, Martino et al.

Entities:  

Keywords:  endoscopic ultrasound (eus); esophagogastroduodenoscopy (egd); gastrinoma; multiple endocrine neoplasia type 1 (men1); zollinger-ellison syndrome

Year:  2022        PMID: 35919366      PMCID: PMC9338823          DOI: 10.7759/cureus.26468

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  14 in total

Review 1.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

Authors:  Rajesh V Thakker; Paul J Newey; Gerard V Walls; John Bilezikian; Henning Dralle; Peter R Ebeling; Shlomo Melmed; Akihiro Sakurai; Francesco Tonelli; Maria Luisa Brandi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-20       Impact factor: 5.958

2.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

Review 3.  Zollinger-Ellison syndrome: classical considerations and current controversies.

Authors:  Irene Epelboym; Haggi Mazeh
Journal:  Oncologist       Date:  2013-12-06

4.  Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

Authors:  Homayoun Shojamanesh; Fathia Gibril; Adeline Louie; Jeremiah V Ojeaburu; Showkat Bashir; Alaa Abou-Saif; Robert T Jensen
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

5.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 6.  Management of patients with Zollinger-Ellison syndrome.

Authors:  J B Meko; J A Norton
Journal:  Annu Rev Med       Date:  1995       Impact factor: 13.739

7.  Radiotherapy for pancreatic neuroendocrine tumors.

Authors:  Joseph N Contessa; Kent A Griffith; Elizabeth Wolff; William Ensminger; Mark Zalupski; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

Review 8.  The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Authors:  Valentina Guarnotta; Chiara Martini; Maria Vittoria Davì; Genoveffa Pizza; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

9.  Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Authors:  S Faivre; P Niccoli; D Castellano; J W Valle; P Hammel; J-L Raoul; A Vinik; E Van Cutsem; Y-J Bang; S-H Lee; I Borbath; C Lombard-Bohas; P Metrakos; D Smith; J-S Chen; P Ruszniewski; J-F Seitz; S Patyna; D R Lu; K J Ishak; E Raymond
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

10.  Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle.

Authors:  Rong-Hsin Yang; Yum-Kung Chu
Journal:  Radiol Case Rep       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.